ProQR Therapeutics N.V. (PRQR)
PRQR Stock Price Chart
Explore ProQR Therapeutics N.V. interactive price chart. Choose custom timeframes to analyze PRQR price movements and trends.
PRQR Company Profile
Discover essential business fundamentals and corporate details for ProQR Therapeutics N.V. (PRQR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Sept 2014
Employees
166.00
Website
https://www.proqr.comCEO
Daniel Anton de Boer
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
PRQR Financial Timeline
Browse a chronological timeline of ProQR Therapeutics N.V. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.10, while revenue estimate is $7.05M.
Earnings released on 7 Aug 2025
EPS came in at -$0.14 falling short of the estimated -$0.08 by -75.00%, while revenue for the quarter reached $4.49M , missing expectations by -18.16%.
Earnings released on 8 May 2025
EPS came in at -$0.11 falling short of the estimated -$0.09 by -22.22%, while revenue for the quarter reached $4.95M , beating expectations by +3.10%.
Earnings released on 13 Mar 2025
EPS came in at -$0.10 matching the estimated -$0.10, while revenue for the quarter reached $4.46M , missing expectations by -18.10%.
Earnings released on 7 Nov 2024
EPS came in at -$0.11 surpassing the estimated -$0.12 by +8.33%, while revenue for the quarter reached $4.21M , missing expectations by -39.81%.
Earnings released on 8 Aug 2024
EPS came in at -$0.03 surpassing the estimated -$0.12 by +75.00%, while revenue for the quarter reached $6.81M , missing expectations by -43.41%.
Earnings released on 9 May 2024
EPS came in at -$0.10 surpassing the estimated -$0.12 by +16.67%, while revenue for the quarter reached $4.81M , beating expectations by +70.48%.
Earnings released on 13 Mar 2024
EPS came in at -$0.08 matching the estimated -$0.08, while revenue for the quarter reached $3.52M , missing expectations by -79.81%.
Earnings released on 7 Nov 2023
EPS came in at -$0.08 falling short of the estimated -$0.06 by -33.33%, while revenue for the quarter reached $1.45M , missing expectations by -88.58%.
Earnings released on 3 Aug 2023
EPS came in at -$0.11 surpassing the estimated -$0.12 by +8.33%, while revenue for the quarter reached $1.31M , missing expectations by -23.13%.
Earnings released on 16 May 2023
EPS came in at -$0.12 matching the estimated -$0.12, while revenue for the quarter reached $712.12K , missing expectations by -49.85%.
Earnings released on 29 Mar 2023
EPS came in at -$0.16 surpassing the estimated -$0.20 by +20.00%, while revenue for the quarter reached $885.43K , missing expectations by -13.19%.
Earnings released on 9 Nov 2022
EPS came in at -$0.34 falling short of the estimated -$0.23 by -47.83%, while revenue for the quarter reached $933.60K , beating expectations by +13.55%.
Earnings released on 4 Aug 2022
EPS came in at -$0.22 surpassing the estimated -$0.26 by +15.38%, while revenue for the quarter reached $1.07M , beating expectations by +18.44%.
Earnings released on 5 May 2022
EPS came in at -$0.22 surpassing the estimated -$0.25 by +12.00%, while revenue for the quarter reached $1.36M , beating expectations by +53.68%.
Earnings released on 24 Feb 2022
EPS came in at -$0.30 falling short of the estimated -$0.26 by -15.38%, while revenue for the quarter reached $270.96K , missing expectations by -68.42%.
Earnings released on 4 Nov 2021
EPS came in at -$0.26 falling short of the estimated -$0.23 by -13.04%, while revenue for the quarter reached $1.01M , beating expectations by +261.47%.
Earnings released on 5 Aug 2021
EPS came in at -$0.29 falling short of the estimated -$0.26 by -11.54%, while revenue for the quarter reached $288.31K , beating expectations by +20.13%.
Earnings released on 6 May 2021
EPS came in at -$0.30 falling short of the estimated -$0.28 by -7.14%.
Earnings released on 25 Feb 2021
EPS came in at -$0.31 falling short of the estimated -$0.30 by -3.33%.
Earnings released on 16 Nov 2020
EPS came in at -$0.36 falling short of the estimated -$0.27 by -33.33%.
PRQR Stock Performance
Access detailed PRQR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.